This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Scagliotti, G. V. Articles by Hirsch, F. R. Search for Related Content PubMed PubMed Citation Articles by Scagliotti, G. V. Articles by Hirsch, F. R.

The Biology of Epidermal Growth Factor Receptor in Lung Cancer

¹ Department of Clinical and Biological Sciences, S. Luigi Gonzaga, University of Torino, Thoracic Oncology Unit, Torino, Italy, and ² Departments of Medicine and Pathology, University of Colorado Health Sciences Center, Denver, Colorado

The prognostic significance of epidermal growth factor receptor (EGFR) expression in lung cancer and, more importantly, its ability to predict response to anti-EGFR therapies, are currently subjects of active research. In a meta-analysis, EGFR overexpression confirmed a worse prognosis (HR 1.13) in eight studies using immunohistochemistry, although cutoff values were generally selected arbitrarily by investigators. Most applied clinical research on the EGFR has been focused on the overexpression of the receptor, whereas less research has addressed the potential role of other mechanisms of increased signaling or of nonmembrane-bound events. The emerging concept of EGFR signaling reveals a multilayered network that allows for horizontal interactions and permits multiple combinatorial responses that may explain the specificity of cellular outcomes to receptor activation. New technologies such as nucleotide arrays and proteomics will help to elucidate the issue by providing information on how EGFR signaling may affect the expression of genes and proteins in cancer cells.

This article has been cited by other articles:

				M. H Nelson and C. R Dolder Lapatinib: A Novel Dual Tyrosine Kinase Inhibitor with Activity in Solid Tumors Ann. Pharmacother., February 1, 2006; 40(2): 261 - 269. [Abstract] [Full Text] [PDF]

				C. D. Thienelt, P. A. Bunn Jr, N. Hanna, A. Rosenberg, M. N. Needle, M. E. Long, D. L. Gustafson, and K. Kelly Multicenter Phase I/II Study of Cetuximab With Paclitaxel and Carboplatin in Untreated Patients With Stage IV Non-Small-Cell Lung Cancer J. Clin. Oncol., December 1, 2005; 23(34): 8786 - 8793. [Abstract] [Full Text] [PDF]